Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.58 USD | +2.27% | -4.77% | -21.56% |
Feb. 26 | Morgan Stanley Trims Veracyte's Price Target to $21 From $22, Keeps Underweight Rating | MT |
Feb. 23 | Sector Update: Health Care Stocks Mixed Premarket Friday | MT |
Financials (USD)
Sales 2024 * | 398M | Sales 2025 * | 443M | Capitalization | 1.58B |
---|---|---|---|---|---|
Net income 2024 * | -17M | Net income 2025 * | -3M | EV / Sales 2024 * | 3.42 x |
Net cash position 2024 * | 220M | Net cash position 2025 * | 266M | EV / Sales 2025 * | 2.97 x |
P/E ratio 2024 * |
-89.9
x | P/E ratio 2025 * |
-518
x | Employees | 815 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.57% |
Latest transcript on Veracyte, Inc.
1 day | +2.27% | ||
1 week | -5.02% | ||
Current month | -8.37% | ||
1 month | -12.77% | ||
3 months | -23.39% | ||
6 months | -13.85% | ||
Current year | -21.56% |
Managers | Title | Age | Since |
---|---|---|---|
Marc Stapley
CEO | Chief Executive Officer | 54 | 21-05-31 |
Rebecca Chambers
DFI | Director of Finance/CFO | 46 | 21-07-18 |
Steven French
CTO | Chief Tech/Sci/R&D Officer | - | 22-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Evan Jones
BRD | Director/Board Member | 67 | 08-01-31 |
Robert Epstein
CHM | Chairman | 69 | 15-01-11 |
Karin Eastham
BRD | Director/Board Member | 74 | 12-11-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-18 | 21.58 | +2.27% | 961,770 |
24-03-15 | 21.1 | -0.75% | 2,608,045 |
24-03-14 | 21.26 | -3.67% | 650,425 |
24-03-13 | 22.07 | -1.12% | 674,195 |
24-03-12 | 22.32 | -1.50% | 695,816 |
Delayed Quote Nasdaq, March 18, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.56% | 1.58B | |
-20.44% | 10.48B | |
+72.57% | 3.89B | |
-6.29% | 2.47B | |
-35.49% | 2.16B | |
+21.53% | 1.02B | |
+5.46% | 845M | |
-17.58% | 525M | |
-35.10% | 470M | |
+10.80% | 257M |